title: Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment.
abstract: Glioblastoma multiforme (GBM) has a very poor prognosis, despite multimodal therapy including surgery, radiation and chemotherapy. A novel adoptive immunotherapy that exploits the presence of cytomegalovirus antigens in malignant brain cancer cells has been shown to be safe and elicit potential clinical benefit for the treatment of recurrent GBM.
authors.affiliation: QIMR Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory; Department of Immunology; QIMR Berghofer Medical Research Institute; Brisbane, QLD Australia.
authors.forename: Andrea
authors.initials: A
authors.lastname: Schuessler
authors.affiliation: Newro Foundation; The Wesley Hospital; Brisbane, QLD Australia.
authors.forename: David G
authors.initials: DG
authors.lastname: Walker
authors.affiliation: QIMR Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory; Department of Immunology; QIMR Berghofer Medical Research Institute; Brisbane, QLD Australia.
authors.forename: Rajiv
authors.initials: R
authors.lastname: Khanna
keywords: adoptive immunotherapy; clinical trial; cytomegalovirus; cytotoxic T cells; recurrent glioblastoma multiforme
references.citation: Clin Cancer Res. 2014 May 15;20(10):2684-94
references.pmid: 24658154
references.citation: Virus Res. 2011 May;157(2):193-203
references.pmid: 21036194
references.citation: Expert Rev Vaccines. 2013 Jun;12(6):597-615
references.pmid: 23750791
references.citation: Immunol Cell Biol. 2012 Oct;90(9):872-80
references.pmid: 22508289
references.citation: Cancer Res. 2014 Jul 1;74(13):3466-76
references.pmid: 24795429
references.citation: Cancer Res. 2002 Jun 15;62(12):3347-50
references.pmid: 12067971
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009